Course
Beyond VISION: New Indications, Radionuclides, and Targets in Nuclear Medicine Theranostics
In this archived one-hour OAMRS Webinar presentation, Dr. Jeremie Calais summarizes how the VISION trial established 177Lu-PSMA-617 as a standard of care in metastatic castration-resistant prostate cancer and set the foundation for modern radioligand therapy.
Online 1 hour Available now
About this course
Year: 2026
Prerequisites: None
How you’ll attend
Join live (Thu 7 pm or Fri 7 am), watch the replay, or take the short modules. One registration covers all three.
Choose how you attendAt a glance
- Learning hours
- 1 hour
- Type of learning
- Online
- Completion requirement
- Watch the entire length of the video.
- Product code
- OCTWEB26